Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 66

Related Articles by Review for PubMed (Select 18702780)

1.

The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22.

Raina R, Pahlajani G, Ponsky LE, Agarwal A, Zippe CD.

BJU Int. 2008 Aug;102(3):297-300. doi: 10.1111/j.1464-410X.2008.07789.x.

PMID:
18702780
2.

Urine cytology. It is still the gold standard for screening?

Brown FM.

Urol Clin North Am. 2000 Feb;27(1):25-37. Review.

PMID:
10696242
3.

[Urinary cytology in cases of bladder cancer: a critical evaluation].

Rathert P.

Urologe A. 2003 Jul;42(7):908-11. Epub 2003 Mar 26. Review. German.

PMID:
12898033
4.
5.

[Urinary tumor marker for urothelial cancer].

Ohtani M, Iwasaki A, Shiraiwa H.

Gan To Kagaku Ryoho. 2001 Nov;28(12):1933-7. Review. Japanese.

PMID:
11729491
6.

New methods for detection of bladder cancer.

Grossman HB.

Semin Urol Oncol. 1998 Feb;16(1):17-22. Review.

PMID:
9508078
7.

NMP22 BladderChek Test: point-of-care technology with life- and money-saving potential.

Tomera KM.

Expert Rev Mol Diagn. 2004 Nov;4(6):783-94. Review.

PMID:
15525221
8.

Urinary markers of bladder carcinoma.

Dey P.

Clin Chim Acta. 2004 Feb;340(1-2):57-65. Review.

PMID:
14734196
9.

Defining the role of NMP22 in bladder cancer surveillance.

Nguyen CT, Jones JS.

World J Urol. 2008 Feb;26(1):51-8. Epub 2007 Dec 4. Review.

PMID:
18058108
10.

[Diagnostic test for bladder cancer: the NMP22®].

Saint F, Quintens H, Roupret M, Amsellem-Ouazana D, Mazerolles C, Wallerand H, Bernardini S, Guy L, Soulié M, Pfister C; Sous-comité vessie du Comité de cancérologie de l'AFU.

Prog Urol. 2011 Apr;21(4):245-9. doi: 10.1016/j.purol.2010.09.027. Epub 2011 Jan 7. Review. French.

PMID:
21482397
11.

[Molecular markers for transitional cell carcinoma of bladder].

Kleinmann J, Siegel YI, Zisman A.

Harefuah. 2003 Jul;142(7):531-5, 565. Review. Hebrew.

PMID:
12908389
12.

Urinary markers in screening patients with hematuria.

Chiong E, Gaston KE, Grossman HB.

World J Urol. 2008 Feb;26(1):25-30. Epub 2007 Dec 4. Review.

PMID:
18060548
13.

[Non-invasive urinary diagnosis of bladder cancer. What do we know?].

Kausch I, Böhle A.

Urologe A. 2003 Jul;42(7):912-21. Epub 2003 Apr 11. Review. German.

PMID:
12898034
14.

Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer.

Herman MP, Svatek RS, Lotan Y, Karakiewizc PI, Shariat SF.

Minerva Urol Nefrol. 2008 Dec;60(4):217-35. Review.

PMID:
18923359
15.

[Value of urinary markers in the diagnosis and follow-up of urothelial bladder tumours].

Campos-Fernandes JL, Descotes F, André J, Perrin P, Devonec M, Ruffion A.

Prog Urol. 2007 Feb;17(1):23-34. Review. French.

PMID:
17373233
16.

Urine markers for bladder cancer surveillance: a systematic review.

van Rhijn BW, van der Poel HG, van der Kwast TH.

Eur Urol. 2005 Jun;47(6):736-48. Epub 2005 Mar 23. Review.

PMID:
15925067
17.

Tumor markers in the diagnosis of primary bladder cancer. A systematic review.

Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH.

J Urol. 2003 Jun;169(6):1975-82. Review.

PMID:
12771702
18.

Can biological markers replace cystoscopy? An update.

van der Poel HG, Debruyne FM.

Curr Opin Urol. 2001 Sep;11(5):503-9. Review.

PMID:
11493772
19.

Telomerase and other novel approaches to bladder cancer detection.

Bennett A.

Clin Lab Sci. 2008 Summer;21(3):185-90; quiz 191-2, following 192. Review.

PMID:
18678141
20.

Utility of nuclear matrix protein (NMP22) in the detection of recurrent bladder cancer.

Grocela JA, McDougal WS.

Urol Clin North Am. 2000 Feb;27(1):47-51, viii. Review.

PMID:
10696244
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk